Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. (CacheMire)

Cross-sectional, Multicentric, Non-interventional Study to Assess the Frequency and the Management of Cachexia and Associated Symptoms in Patients With Non-small Cell Lung Cancer.

The purpose of this study is to assess the frequency of cachexia and the management of cachexia and associated symptoms in a patient population with non-small cell lung cancer (NSCLC).

Study Overview

• Status: Completed
• Conditions: Cachexia; Non-small Cell Lung Cancer

Detailed Description

This is a cross-sectional, non-interventional, European (France and Belgium), multicentric prevalence study, conducted on a representative population of 500 patients with NSCLC, to assess the frequency and the management of cachexia and associated symptoms.

The study will be conducted in accordance with the professional code of ethics and the good epidemiological practices guidelines developed by the ADELF (the Association of French-Speaking Epidemiologists) and in accordance with the STROBE recommendations for the drafting of reports and publications related to the study.

The information will be collected during a single visit to the oncologist/lung specialist as part of the usual patient management of his/her lung cancer. The physician will explain the purpose of the study to the patient with an information form specific to the study and will inform him/her of the option to refuse or withdraw from participation. The patient information form in France or a specific consent form in Belgium will be signed by the patient and a copy will be given to him/her (the original will be kept by the physician).

This study does not require any additional specific data. Data will come from the medical file and from the routine disease management. Furthermore, the following self-completion questionnaires will be proposed to patients: Visual analogue scale for dietary intake (dietary intake VAS), assessment of the concerns associated with the anorexia/cachexia (Anorexia-Cachexia module of the Functional Assessment of Anorexia/Cachexia Therapy [FAACT] questionnaire), quality of life (EORTC QLQ-C30), and assessment of physical activity (IPAQ, International Physical Activity Questionnaire). Abdominal CT-scan, if available, will be collected for assessment of skeletal muscle mass index at L3.

• Study Type: Observational
• Enrollment (Actual): 539

Contacts and Locations

Study Locations

• France
  • Paris, France, 92042
    • Chugai Pharma France

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient with non-small cell lung cancer (NSCLC) from outpatient visit, Day Hospital or in-patient hospitalization.

Description

Inclusion Criteria:

• Patient 18 years of age and older
• Patient with NSCLC
• Patient who has been informed of the study and who has signed a patient information leaflet for France or an informed consent for Belgium
• Patient able to complete a self-assessment questionnaire

Exclusion Criteria:

• Patient unable to consent and/or unable to sign the patient information form in France or an informed consent in Belgium
• Patient with a complete resection of an early stage NSCLC
• History of head and neck cancer

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of Cachexia According to Modified Fearon Criteria	Percentage of NSCLC patients with a cachexia according to Fearon criteria modified for the stages of pre-cachexia and refractory cachexia in order to classify all the featured cases without ambiguity. A patient was considered to have cachexia if he/she had: Weight loss >5% in the last 6 months prior to inclusion or; BMI <20 kg/m² and weight loss between 2 and 5% in the 6 months prior to inclusion or; Weight loss >2% and sarcopenia (as evaluated by the muscle mass index at L3) if available. If data were not available regarding possible sarcopenia, the presence of cachexia was assigned based on the 2 above conditions. In the 3 cases defined above, patient should not have entered the refractory cachexia stage, which was defined as: ECOG performance score of 3 or 4 and a low survival expectancy as defined by Martin et al. (J Clin Oncol 2015) (BMI <20 kg/m² and weight loss ≥ 6%) or (20 ≤ BMI ≤ 21.9 kg/m² and weight loss ≥ 11%) or (22 kg/m² ≤ BMI and weight loss ≥ 15%).	Day1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of the Different Stages of Cachexia in the General NSCLC Population	Percentage of the different stages of cachexia at inclusion. The different stages of cachexia used the following classification: No Cachexia: 1) no weight loss (WL<2%) or 2) weight gain AND no anorexia AND no sarcopenia; The pre-cachexia stage : 1) 2% ≤ weight loss ≤ 5% AND BMI ≥ 20 and/or 2) anorexia (according to question 13 of the quality of life questionnaire QLQ-C30) and/or 3) weight loss < 2% AND sarcopenia; Cachexia: 1) Weight loss > 5% OR 2) weight loss between 2 and 5% AND BMI < 20 kg/m² OR 3) weight loss > 2% AND sarcopenia. In all cases, patient should not have entered the refractory cachexia stage; Refractory cachexia: ECOG 3 or 4 AND low survival expectancy [BMI < 20kg/m² and weight loss ≥ 6%] OR [20 ≤ BMI ≤ 21,9 kg/m² and weight loss ≥ 11%] OR [22 kg/m² ≤ BMI and weight loss ≥ 15%]	Day 1
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC.	Percentage of the different stages of cachexia at inclusion according to the NSCLC stage	Day 1
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC.	Percentage of the different stages of cachexia according to the NSCLC histology	Day 1
Frequency of Sarcopenia in the General NSCLC Patients With Cachexia	Percentage of patients with sarcopenia in the general NSCLC patients with cachexia	Day 1
Frequency of Sarcopenia With no Clinical Significant Weight Loss in the General NSCLC Patients With Pre-cachexia	Percentage of patient with sarcopenia and no clinical significant weight loss (sarcopenia and WL< 2%) in the general NSCLC patients with pre-cachexia:	Day 1
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC.	Percentage of the different stages of cachexia according to the molecular abnormalities associated with NSCLC: EGRF, ALK, ROS1, BRAF or HER2; K-RAS; No mutation	Day 1
Frequency of the Different Stages of Cachexia According to the Number of Treatments Received.	NSCLC patients. 84 patients with missing data	Day 1
Frequency of the Different Stages of Cachexia According to the Types of Treatments Received.	Stage of cachexia at inclusion according to the type of treatments received (surgery, radiotherapy, chemotherapy, targeted therapies).	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State	• Nutritional state according to the different stages of cachexia The variables used will be: serum albumin levels, serum pre-albumin levels, BMI and weight.	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose	Blood glucose abnormalities according to the different stages of cachexia at inclusion	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale	Dietary Intake Visual Analog Scale (Dietary intake VAS): The question "Could you indicate the amount you currently eat, placing a vertical mark on the line between "nothing at all" and "as usual"? ". Depending on the location of the patient mark on the scale, a score of between 0 ("nothing at all") and 10 ("as usual") will be allocated.	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT	Score of the 12-question AC/S module (Anorexia-Cachexia module) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire assessing anorexia and cachexia: the AC/S module of the FAACT questionnaire consists of 12 questions to assess over the last 7 days quality of life, related to anorexia or cachexia. The score ranges between 0 and 48, the higher the score, the higher the quality of life.	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio	neutrophil/lymphocyte ratio	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP	CRP level	Day 1
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen	fibrinogen level	Day 1
Description of the Quality of Life Associated With the Different Stages of Cachexia.	Quality of life has been analysed using scores from the functional scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 items (EORTC QLQ-C30 questionnaire): score ranging from 0 (malfunction) to 100 (healthy level of functioning) for the following parameters : physical, role, cognitive, emotional and social scales	Day 1
Description of the Level of Physical Activity Associated With the Different Stages of Cachexia.	Three levels of physical activity are defined: - LowNo activity is reported ORAn activity is reported but does not reach moderate or high levels.; - ModerateCorresponds to one of the following 3 criteria:3 or more days of intense activity lasting at least 20 min per day OR5 or more days of moderate intensity activity and / or walking for at least 30 min per day OR5 or more days of activity combining walking, activities of moderate or high intensity, thus achieving at least 600 MET-minutes / week; - High Corresponds to one of the following 2 criteria: Intense activity at least 3 days a week and at least 1500 MET-minutes / week OR; 7 or more days of activity combining walking, moderate and high intensity activities, achieving at least 3000 MET-minutes / week	Day 1
Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms	Pharmacological treatment of cachexia or associated symptoms: Yes / No	Day 1
Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms	Non-pharmacological treatment of cachexia or associated symptoms: Y/N	Day 1
Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments	Treatments with systemic corticosteroids, anti-inflammatory drugs, Omega 3 fatty acids: Yes/No	Day 1
Number of Participants With Diabetes Treatments	Diabetes treatments : Yes/No	Day 1
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia	Proportion of patients with cachexia according to the subjective assessment of the clinician; Proportion of patients with cachexia according to the Fearon criteria	Day 1
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia	Proportion of patients with anorexia according to the subjective assessment of the clinician; Proportion of patients with anorexia according to the Ingesta VAS; Proportion of patients with anorexia according to the AC/S-FAACT module score; Proportion of patients with anorexia according to question 13 of the QLQ-C30 questionnaire: "Have you had a lack of appetite?"	Day 1
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition	Proportion of patients with severe malnutrition according to the subjective assessment of the clinician; Proportion of patients with severe malnutrition according to the malnutrition criteria defined by the HAS.	Day 1

Collaborators and Investigators

• Sponsor: Chugai Pharma France
• Collaborators: French College of General Hospital Pneumologists (CPHG); French-Speaking Association of Supportive Care in Cancer (AFSOS); ITEC Services
• Investigators: Study Director: Luz Bobadilla, MD, Chugai Pharma France

Publications and helpful links

General Publications

• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4.

Study record dates

Study Major Dates

• Study Start: July 1, 2016
• Primary Completion (Actual): October 1, 2016
• Study Completion (Actual): October 1, 2016

Study Registration Dates

• First Submitted: November 17, 2016
• First Submitted That Met QC Criteria: November 18, 2016
• First Posted (Estimate): November 21, 2016

Study Record Updates

• Last Update Posted (Actual): September 24, 2019
• Last Update Submitted That Met QC Criteria: September 12, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Keywords: Malnutrition; Cachexia; Anorexia; Non-Small Cell Lung cancer
• Additional Relevant MeSH Terms: Metabolic Diseases; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Nutrition Disorders; Body Weight; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Body Weight Changes; Emaciation; Weight Loss; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Wasting Syndrome; Cachexia
• Other Study ID Numbers: CPF-ANA-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No